Basilea Pharmaceutica

Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.

Equities

Equities by Sector

Sectors

Thematics

Latest

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Listed companies can no longer afford to ignore retail investors

Audiovisual

Latest

The Law Debenture Corporation in 60 seconds

Team Internet – executive interview

Take on Trusts – March 2025

About Edison

About Edison

Careers

Basilea Pharmaceutica (SIX: BSLN)

Latest Insights

Basilea (SIX: BSLN) bags a US$2.5m milestone payment

Basilea Pharmaceutica — Another year, another market beat

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Basilea Pharmaceutica (SIX: BSLN) records first commercial milestone payment from Japan

Sector

Equity Analyst

Key Management

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in

Basilea Pharmaceutica — Need for innovation against severe infections

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Basilea Pharmaceutica — Strong Cresemba traction triggers milestone payment

Interview with David Veitch, CEO of Basilea Pharmaceutica

Basilea Pharmaceutica — From strength to strength

Basilea Pharmaceutica — Strong close to FY23 with another milestone payment

Basilea Pharmaceutica — Antibiotic addition to further replenish pipeline

Basilea Pharmaceutica — Refilling the pipeline for growth

Edison’s most frequently asked questions – Basilea Pharmaceutica

Basilea Pharmaceutica — Incremental acquisition to arsenal; new guidance

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Growth pivot with potential antibacterial addition

Basilea Pharmaceutica — Antifungal addition to bolster pipeline

Basilea Pharmaceutica — New data support FDA application for ceftobiprole

Basilea Pharmaceutica — FDA accepts New Drug Application for ceftobiprole

Basilea Pharmaceutica — Zevtera (ceftobiprole) clinical data published

Basilea Pharmaceutica — A strong start to FY23 across the board

Basilea Pharmaceutica — Zevtera back on track: NDA submitted to the FDA

Basilea Pharmaceutica — Prompt receipt of milestone payments for Cresemba

Basilea Pharmaceutica — Zevtera NDA submission pushed to Q323

Basilea Pharmaceutica — Cresemba expansion continues with Japan launch

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Profitability sooner than expected

Basilea Pharmaceutica — Strong execution resulting in operating profitability

Basilea Pharmaceutica — Revenue upside surprise for 2022

Basilea Pharmaceutica — Cresemba milestone payment triggered

Basilea Pharmaceutica — Third leg of strategy executed with debt repayment

Basilea Pharmaceutica — Oncology milestone payment triggered

Basilea Pharmaceutica — Third oncology asset sale announced, as planned

Basilea Pharmaceutica — New supportive data from ERADICATE

Basilea Pharmaceutica — Oncology asset sales continue

Basilea Pharmaceutica — Strategic streamlining – sale of oncology assets

Basilea Pharmaceutica — To retire converts with senior secured and cash

Basilea Pharmaceutica — On track for operating profitability in FY23

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Zevtera path to US approval open

Basilea Pharmaceutica — Anti-infective refocusing on schedule

Basilea Pharmaceutica — Cresemba IV formulation approved in China

Basilea Pharmaceutica — Yet another milestone payment from Pfizer

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Renewed focus on anti-infectives

Basilea Pharmaceutica — Spring into a new strategy

Basilea Pharmaceutica — Momentum continues

Basilea Pharmaceutica — Multiple catalysts on the horizon

Basilea Pharmaceutica — Derazantinib spearheads oncology portfolio

Basilea Pharmaceutica — A tale of two halves

Basilea Pharmaceutica – executive interview

Executive interview – Basilea Pharmaceutica

Basilea Pharmaceutica — Cresemba sales the focus for future profitability

Basilea Pharmaceutica — 2020 vision on derazantinib in iCCA

Basilea Pharmaceutica — Data-driven catalysts ahead

Basilea Pharmaceutica — Ceftobiprole hits its TARGET

Executive interview – Basilea Pharmaceutica